Aktis Oncology, Inc.
Updated: 18 Jun 2026
No signal published yet
We already track Aktis Oncology and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.
Email when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Temporary check — not Firelda's published signal.
General analysis — not personal advice.
Want to follow Aktis Oncology, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Aktis Oncology free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Recent News
In May 2024, the company entered into a strategic collaboration with Eli Lilly worth up to $1.1 billion to develop novel radiopharmaceutical therapies. This followed a $175 million Series B financing round completed in September 2024 to accelerate the clinical development of its lead programs.
What Firelda Watch includes for Aktis Oncology, Inc.
Add the company to your watchlist and get all of this automatically.
- Free: 3 companies on your watchlist
- Change history and monitoring for every company you follow
- Sunday weekly brief — a short weekly roundup
- Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
Want to follow Aktis Oncology, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Aktis Oncology free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more